Flexion Therapeutics to Present at the 2014 Jefferies Healthcare Conference


BURLINGTON, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 2014 Jefferies Healthcare Conference. Dr. Clayman's presentation is scheduled for June 2, 2014, at 10:30 a.m. Eastern Time. The conference will take place June 2-5, 2014, in New York, NY.

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.



            

Contact Data